$633.7 M

AKBA Mkt cap, 14-Jun-2018
Akebia Therapeutics Net income (Q1, 2018)-23.4 M
Akebia Therapeutics EBIT (Q1, 2018)-24.5 M
Akebia Therapeutics Cash, 31-Mar-2018158.2 M

Akebia Therapeutics Financials

Akebia Therapeutics Income Statement

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017

R&D expense

25.4 m43 m115.8 m230.9 m

General and administrative expense

12.5 m18.5 m22.2 m27 m

Operating expense total

37.9 m61.5 m138 m257.9 m

EBIT

(37.9 m)(61.5 m)(136.5 m)(79.9 m)

Interest expense

206 k510 k

Interest income

206 k510 k901 k2.8 m

Net Income

(37 m)(60.7 m)(135.7 m)(76.9 m)

Quarterly

USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

R&D expense

7.5 m7.2 m15.8 m20.2 m30.9 m31.2 m60 m43.8 m61.4 m

General and administrative expense

3.4 m3.7 m3.9 m5.8 m5.3 m4.9 m5.8 m6.9 m9 m

Operating expense total

10.9 m10.9 m19.7 m26 m36.2 m36.2 m65.8 m50.7 m70.4 m

EBIT

(10.9 m)(10.9 m)(19.7 m)(26 m)(36.2 m)(36.2 m)(45 m)(22.1 m)(24.5 m)

Interest expense

96 k116 k139 k234 k

Interest income

96 k116 k139 k234 k270 k219 k435 k608 k1.1 m

Net Income

(10.7 m)(10.7 m)(19.5 m)(25.8 m)(35.8 m)(36.3 m)(44.5 m)(21.5 m)(23.4 m)

Akebia Therapeutics Balance Sheet

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017

Cash

32.8 m49.8 m187.3 m70.2 m

Accounts Receivable

48 k933 k34.2 m

Inventories

1.5 m2.6 m2.2 m

Current Assets

110.5 m141 m296.3 m358.4 m

PP&E

209.9 k540 k2.6 m3.6 m

Total Assets

111 m142.9 m300.2 m364.2 m

Accounts Payable

2 m2.3 m2 m7 m

Current Liabilities

6.9 m11.9 m114.3 m144.3 m

Total Liabilities

232.1 m244.9 m

Additional Paid-in Capital

205 m292.8 m365.3 m493.8 m

Retained Earnings

(100.7 m)(161.4 m)(297.1 m)(374.1 m)

Total Equity

104.1 m131 m68.1 m119.3 m

Financial Leverage

1.1 x1.1 x4.4 x3.1 x

Quarterly

USDQ1, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Cash

126.3 m27.9 m76.2 m66.7 m43.4 m46.2 m65.8 m87.3 m125.4 m158.2 m

Accounts Receivable

119.4 k74 k48 k14 k35.9 m

Current Assets

133.7 m102.7 m155 m158.8 m219.5 m192.5 m165.1 m255.1 m332.4 m437 m

PP&E

404 k398 k479 k629 k1.8 m2.7 m2.9 m2.9 m3.7 m

Total Assets

134 m103.5 m155.7 m159.6 m221.4 m195.6 m169.1 m259.3 m336.8 m442.7 m

Accounts Payable

2.1 m4.3 m2.4 m5.3 m2.4 m5.1 m8.5 m15.1 m10.2 m17.9 m

Current Liabilities

6.1 m8.8 m5.9 m14.2 m13.4 m20.9 m26.1 m133.5 m181.6 m151.4 m

Total Liabilities

6.2 m8.9 m5.9 m14.2 m53.7 m62.3 m68.4 m228.6 m279.8 m245.6 m

Additional Paid-in Capital

201.2 m206.1 m272 m287.1 m355.1 m356.2 m360 m372.5 m420.4 m591.9 m

Retained Earnings

(111.4 m)(122.1 m)(141.5 m)(187.2 m)(223 m)(259.3 m)(341.7 m)(363.2 m)(394.2 m)

Total Equity

127.9 m94.6 m149.8 m145.4 m167.8 m133.3 m100.7 m30.6 m57 m197.1 m

Financial Leverage

1 x1.1 x1 x1.1 x1.3 x1.5 x1.7 x8.5 x5.9 x2.2 x

Akebia Therapeutics Cash Flow

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(37 m)(60.7 m)(135.7 m)(76.9 m)

Depreciation and Amortization

49.4 k96 k296 k617 k

Accounts Receivable

87 k(393 k)

Inventories

(773 k)(1 m)428 k

Accounts Payable

4.1 m231 k(274 k)5 m

Cash From Operating Activities

(27.5 m)(52.4 m)57.9 m(56.2 m)

Purchases of PP&E

(229 k)(414 k)(2.7 m)(1.6 m)

Cash From Investing Activities

(65.4 m)(13.7 m)12.7 m(177.3 m)

Cash From Financing Activities

104.4 m83.1 m66.9 m116.2 m

Quarterly

USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Net Income

(9.7 m)(10.7 m)(10.7 m)(19.5 m)(25.8 m)(35.8 m)(36.3 m)(44.5 m)(23.4 m)

Depreciation and Amortization

8.1 k199 k

Accounts Receivable

15.9 k114 k57 k74 k48 k14 k(1.6 m)

Accounts Payable

1.9 m1.5 m3 m4.3 m2.4 m5.3 m2.4 m5.1 m8.5 m15.1 m10.9 m

Cash From Operating Activities

(6 m)(20.3 m)

Purchases of PP&E

(142 k)(296 k)

Cash From Investing Activities

5.4 m12.4 m

Cash From Financing Activities

105.8 m95.9 m

Akebia Therapeutics Ratios

USDY, 2018

Financial Leverage

2.2 x
Report incorrect company information